310 related articles for article (PubMed ID: 16131375)
1. A multicenter assessment of recombinant factor VIIa off-label usage: clinical experiences and associated outcomes.
MacLaren R; Weber LA; Brake H; Gardner MA; Tanzi M
Transfusion; 2005 Sep; 45(9):1434-42. PubMed ID: 16131375
[TBL] [Abstract][Full Text] [Related]
2. Single-center experience: use of recombinant factor VIIa for acute life-threatening bleeding in children without congenital hemorrhagic disorder.
Yilmaz D; Karapinar B; Balkan C; Akisü M; Kavakli K
Pediatr Hematol Oncol; 2008 Jun; 25(4):301-11. PubMed ID: 18484474
[TBL] [Abstract][Full Text] [Related]
3. Recombinant activated factor VII in cardiac surgery: experience from the Australian and New Zealand Haemostasis Registry.
Dunkley S; Phillips L; McCall P; Brereton J; Lindeman R; Jankelowitz G; Cameron P
Ann Thorac Surg; 2008 Mar; 85(3):836-44. PubMed ID: 18291152
[TBL] [Abstract][Full Text] [Related]
4. Recombinant activated factor VIIa in uncontrolled bleeding: a haemostasis laboratory study in non-haemophilia patients.
Brandsborg S; Sørensen B; Poulsen LH; Ingerslev J
Blood Coagul Fibrinolysis; 2006 Jun; 17(4):241-9. PubMed ID: 16651865
[TBL] [Abstract][Full Text] [Related]
5. Safety and efficacy of recombinant activated factor VII: a randomized placebo-controlled trial in the setting of bleeding after cardiac surgery.
Gill R; Herbertson M; Vuylsteke A; Olsen PS; von Heymann C; Mythen M; Sellke F; Booth F; Schmidt TA
Circulation; 2009 Jul; 120(1):21-7. PubMed ID: 19546387
[TBL] [Abstract][Full Text] [Related]
6. The use of recombinant activated factor VII in three patients with central nervous system hemorrhages associated with factor VII deficiency.
Huang WY; Kruskall MS; Bauer KA; Uhl L; Shaz BH
Transfusion; 2004 Nov; 44(11):1562-6. PubMed ID: 15504160
[TBL] [Abstract][Full Text] [Related]
7. Recombinant activated factor VII: treating postoperative hemorrhage in cardiac surgery.
Bishop CV; Renwick WE; Hogan C; Haeusler M; Tuckfield A; Tatoulis J
Ann Thorac Surg; 2006 Mar; 81(3):875-9. PubMed ID: 16488687
[TBL] [Abstract][Full Text] [Related]
8. Use of recombinant activated factor VII concentrate to control postoperative hemorrhage in complex cardiovascular surgery.
Bowman LJ; Uber WE; Stroud MR; Christiansen LR; Lazarchick J; Crumbley AJ; Kratz JM; Toole JM; Crawford FA; Ikonomidis JS
Ann Thorac Surg; 2008 May; 85(5):1669-76; discussion 1676-7. PubMed ID: 18442563
[TBL] [Abstract][Full Text] [Related]
9. Efficacy of recombinant activated Factor VII in patients with massive uncontrolled bleeding: a retrospective observational analysis.
Berkhof FF; Eikenboom JC
Transfusion; 2009 Mar; 49(3):570-7. PubMed ID: 19040498
[TBL] [Abstract][Full Text] [Related]
10. [Clinical assessment of potential fields of application of recombinant factor VIIa in internal and pediatric diseases. Recommendations of an expert group].
Dempfle CE; Gulba D; Kirchmaier CM; Klamroth R; Korte W; Lorenz R; Peck-Radosavljevic M; Veldman A; Zotz RB
Med Klin (Munich); 2007 Jan; 102(1):70-81. PubMed ID: 17221356
[TBL] [Abstract][Full Text] [Related]
11. Recombinant activated factor VII (rFVIIa) treatment in infants with hemorrhage.
Brady KM; Easley RB; Tobias JD
Paediatr Anaesth; 2006 Oct; 16(10):1042-6. PubMed ID: 16972833
[TBL] [Abstract][Full Text] [Related]
12. Prolonged prothrombin time after recombinant activated factor VII therapy in critically bleeding trauma patients is associated with adverse outcomes.
McMullin NR; Wade CE; Holcomb JB; Nielsen TG; Rossaint R; Riou B; Rizoli SB; Kluger Y; Choong PI; Warren B; Tortella BJ; Boffard KD;
J Trauma; 2010 Jul; 69(1):60-9. PubMed ID: 20622579
[TBL] [Abstract][Full Text] [Related]
13. Safety of recombinant activated factor VII in randomized clinical trials.
Levi M; Levy JH; Andersen HF; Truloff D
N Engl J Med; 2010 Nov; 363(19):1791-800. PubMed ID: 21047223
[TBL] [Abstract][Full Text] [Related]
14. Comparison of Fresh-Frozen Plasma, Four-Factor Prothrombin Complex Concentrates, and Recombinant Factor VIIa to Facilitate Procedures in Critically Ill Patients with Coagulopathy from Liver Disease: A Retrospective Cohort Study.
Kwon JO; MacLaren R
Pharmacotherapy; 2016 Oct; 36(10):1047-1054. PubMed ID: 27547916
[TBL] [Abstract][Full Text] [Related]
15. Treatment of diffuse alveolar hemorrhage after allogeneic bone marrow transplant with recombinant factor VIIa.
Hicks K; Peng D; Gajewski JL
Bone Marrow Transplant; 2002 Dec; 30(12):975-8. PubMed ID: 12476294
[TBL] [Abstract][Full Text] [Related]
16. Complications of recombinant activated human coagulation factor VII.
Howes JL; Smith RS; Helmer SD; Taylor SM
Am J Surg; 2009 Dec; 198(6):895-9. PubMed ID: 19969148
[TBL] [Abstract][Full Text] [Related]
17. Effect of recombinant activated factor VII in critical bleeding: clinical experience of a single center.
Sartori MT; Imbergamo S; Zanon E; Bonaccorso G; Pittoni G; Feltracco P; Ori C; Pagnan A; Cella G
Clin Appl Thromb Hemost; 2009 Dec; 15(6):628-35. PubMed ID: 19605376
[TBL] [Abstract][Full Text] [Related]
18. Experience with recombinant-activated factor VII in 30 patients with congenital factor VII deficiency.
Brenner B; Wiis J
Hematology; 2007 Feb; 12(1):55-62. PubMed ID: 17364994
[TBL] [Abstract][Full Text] [Related]
19. Pediatric off-label use of recombinant factor VIIa.
Alten JA; Benner K; Green K; Toole B; Tofil NM; Winkler MK
Pediatrics; 2009 Mar; 123(3):1066-72. PubMed ID: 19255041
[TBL] [Abstract][Full Text] [Related]
20. Use of recombinant activated factor VII for intractable bleeding in patients without hemophilia: A developing country tertiary care center's experience.
Musallam KM; Saad GS; Majdalani MN; Muwakkit SA; Bou-Khalil PK; Aoun EG; Sawaya RA; Khalil I; Taher AT
Clin Appl Thromb Hemost; 2010 Dec; 16(6):658-62. PubMed ID: 19671562
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
